Navigation Links
Juno Closes $134M Series B Round
Date:8/5/2014

SEATTLE, Aug. 5, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc., a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced that it has closed its Series B round with $134M in new investment.

This latest round includes new investments by ten public mutual funds and healthcare-focused funds. All major prior investors participated as well. The company will use proceeds from the Series B round to continue advancing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.

Juno announced the close of its $176M Series A in April. Combining the A and B rounds, Juno has raised more than $300M in less than 12 months.

"Juno continues to make significant progress in developing new therapies with the potential to radically change the outlook for patients battling cancer," said Hans Bishop, CEO of Juno. "We are delighted by the vote of confidence coming from new Series B investors and founding investors alike. Our funding puts us in a strong position to move forward with multiple CAR-T and TCR therapies and invest in the science that will support continued innovation with these game-changing technologies."

Leerink Partners LLC acted as exclusive financial advisor in this transaction.

Juno Therapeutics launched in December 2013 and was co-founded with financial support from ARCH Venture Partners and the Alaska Permanent Fund through a partnership managed by Crestline Investors.

About Juno

Juno is a clinical stage company that brings together innovative technologies from three of the world's leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center and Seattle Children's Research Institute – to advance a broad pipeline of potential curative immunotherapy treatments. Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Logo - http://photos.prnewswire.com/prnh/20140113/DC45426LOGO


'/>"/>
SOURCE Juno Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. CTD Holdings Closes $1.725 Million Private Placement
2. BioMedomics, Inc. Closes $690K Round of Financing
3. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
4. Z Trim Holdings Closes 2013 With Record Sales
5. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
6. Fluential Closes $8 Million Series A Round to Drive Natural Language Product Development
7. Z Trim Holdings, Inc. Closes $1.4 Million Public Offering
8. Sensible Medical Innovations Closes on Financing Round Led by Boston Scientific Corporation
9. Terascala Closes Additional Funding Based on Strong OEM Sales and Release of ISB
10. VG Life Sciences, Inc. Closes on $2,235,000 from Private Fund
11. Pittsburgh Life Sciences Greenhouse Closes $315,000 In Half-Year Investments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... ... Biova, LLC., the leader in water soluble egg membrane ingredients, announced today ... bring a wealth of scientific experience in the food, beverage, nutrition and dietary supplement ... of four major global companies in the last 4 decades. He has a ...
(Date:6/23/2017)... and CARDIFF, UK (PRWEB) , ... June 23, 2017 , ... ... and Brian Lula, president of Physik Instrumente USA, have been selected as this year’s ... photonics . , The two have been invited along with other honorees to accept ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... for model aircraft flying hobbyists, and the University Aviation Association (UAA), the unifying ... students. The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through a ...
(Date:6/22/2017)... ... 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. announces the ... to manage the new site. , Tim has 25 years of pharmaceutical experience, ... role as the Director of Manufacturing and Supplier Quality Assessment. This group ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):